Multiple sclerosis (MS) is a chronic neurodegenerative disease characterized by
inflammation and demyelination for which there is currently no cure; therefore, the aim of …

Monoclonal antibodies have become a mainstay in the treatment of patients with relapsing
multiple sclerosis (RMS) and provide some benefit to patients with primary progressive MS …

Background multiple sclerosis (MS) patients are treated with immunomodulatory treatments
that can influence their ability to develop a protective antibody response to the SARS-CoV-2 …

Introduction To evaluate the impact of the COVID-19 pandemic on (1) number of clinical
visits,(2) magnetic resonance (MR) scans, and (3) treatment prescriptions in a multiple …

The SARS-CoV-2 pandemic has raised particular concern for people with Multiple Sclerosis,
as these people are believed to be at increased risk of infection, especially those being …

The purpose of this literature review was to summarise relevant findings regarding the
clinical management of multiple sclerosis (MS) in the COVID-19 pandemic, with the focus on …

Introduction Dimethyl fumarate (DMF) is approved as oral systemic treatment for moderate-to-
severe psoriasis. Scarce evidence is available for DMF treatment in psoriatic patients at the …

Background: The SARS-CoV-2 pandemic represents one of the most challenging issues that
have recently influenced everyday life in countries all over the world. Understanding the risk …

Background The outbreak of coronavirus disease 2019 (COVID-19) has rapidly spread and
developed as a pandemic threatening global health. Patients with multiple sclerosis (MS) …

Introduction COVID-19 pandemic is thought to influence the natural history of immune
disorders, yet the knowledge on its effect on multiple sclerosis (MS) is unknown and not fully …